Erratum to New oral anticoagulants in atrial fibrillation: A reappraisal of trial results looking at absolute figures (Intern Emerg Med, (2013), 8, (115-122), 10.1007/s11739-012-0886-6);New oral anticoagulants in atrial fibrillation: A reappraisal of trial results looking at absolute figures

Internal and Emergency Medicine

Volumn 8, Issue 2, 2013, Pages 115-122

  Coccheri, Sergio ^a   Orlando, Donatella ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Center of Cardiovascular Medicine   (Italy)

Author keywords

Apixaban; Atrial fibrillation; Dabigatran; Intracranial bleeding; New oral anticoagulants; Rivaroxaban; Stroke

Indexed keywords

EID: 84874364445     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-013-0962-6     Document Type: Erratum

References (41)

1. Hart RG, Pearce LA, Aguilar MI (2007) Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med 147: 590-592.
2. Nieuwlaat R, Olsson SB, Lip GY, Euro Heart Survey Investigators et al (2007) Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation. Am Heart J 153: 1006-1012.
3. Olesen JB, Lip GY, Lindhardsen J et al (2011) Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a "real world" nationwide cohort study. Thromb Haemost 106: 739-749.
4. Bauer KA (2011) Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa. J Thromb Haemost 9: 12-19.
5. Connolly SJ, Ezekowitz MD, Yusuf S, RE-LY Steering Committee and Investigators et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361: 1139-1151.
6. Patel MR, Mahaffey KW, Garg J, The ROCKET AF Steering Committee for the ROCKET AF Investigators et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365: 883-891.
7. Granger CB, Alexander JH, McMurray JJV, The ARISTOTLE Committees and Investigators et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365: 981-992.
8. Hohnloser SH, Oldgren J, Yang S et al (2012) Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation 125: 669-676.
9. Cairns J (2012) Review: dabigatran increases MI and reduces mortality compared with warfarin, enoxaparin, or placebo. Ann Intern Med 156: JC6-JC11.
10. Diener HC, Connolly SJ, Ezekowitz MD, RE-LY Study Group et al (2010) Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 9: 1157-1163.
11. Hankey GJ, Patel MR, Stevens SR et al (2012) Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 11: 315-322.
12. Easton JD, Lopes RD, Bahit MC et al (2012) Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol 11: 503-511.
13. Connolly SJ, Eikelboom J, Joyner C, For the AVERROES Steering Committee and Investigators et al (2011) Apixaban in patients with atrial fibrillation. N Engl J Med 364: 806-817.
14. Warkentin AE, Donadini MP, Spencer FA et al (2012) Bleeding risk in randomized controlled trials comparing warfarin and aspirin: a systematic review and meta-analysis. J Thromb Haemost 10: 512-520.
15. Lawrence J, Pogue J, Synhorst D, For the AVERROES Steering Committee and Investigators et al (2012) Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomized trial. Lancet Neurol 11: 225-231.
16. Mannucci PM, Nobili A, Garattini S (2012) New drugs for thromboprophylaxis in atrial fibrillation. Eur J Int Med 23: 1-5 Editorial.
17. Mantha S, Ansell J (2012) An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemost 108: 476-484.
18. Morales-Vidal S, Schneck MJ, Flaster M et al (2012) Direct thrombin inhibitors and factor Xa inhibition in patients with cerebrovascular disease. Expert Rev Neurother 12: 179-190.
19. ESC working group on Thrombosis-Task Force on Anticoagulants in Heart Disease Position Paper (2012) New oral anticoagulants in atrial fibrillation and acute coronary syndromes. J Am Coll Cardiol 59: 1413-1425.
20. Pengo V, Crippa L, Falanga A et al (2012) Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation-a look beyond the excellent results. J Thromb Haemost 10: 1979-1987.
21. Banerjee A, Lane DA, Torp-Pedersen C et al (2012) Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a "real world" atrial fibrillation population: a modeling analysis based on a nationwide cohort study. Thromb Haemost 107: 584-589.
22. Miller CS, Grandi SM, Shimony A et al (2012) Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 110: 453-460.
23. Capodanno D, Capranzano P, Giacchi G et al (2012) Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: a meta-analysis of 50, 578 patients. Int J Cardiol (Epub ahead of print).
24. Lip GYH, Larsen TB, Skjoth F et al (2012) Indirect comparison of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol 60: 738-746.
25. Harenberg J, Marx S, Diener HC et al (2012) Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. Int Angiol 31: 330-339.
26. Wells GA, Coyle D, Cameron C, et al (2012) Safety, effectiveness, and cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. http://www. cadth. ca/media/pdf/NOAC_Therapeutic_Review_final_report. pdf. Assessed 4 July 2012.
27. Baker WL, Phung OJ (2012) Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation. Circ Cardiovasc Qual Outcomes 5: 711-719.
28. Testa L, Agnifili M, Latini RA, et al (2012) Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation. QJM 105: 949-957.
29. Schneeweiss G, Gagne JJ, Patrick AR et al (2012) Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 5(4): 480-486.
30. Kooiman J, van de Pepper WR, van der Meer FJM et al (2011) Incidence of chronic kidney disease in patients with atrial fibrillation and its relevance for prescribing new oral antithrombotic drugs. J Thromb Haemost 9: 1652-1653.
31. Fox KA, Piccini JP, Wojdyla D et al (2011) Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 32: 2387-2394.
32. Hohnloser SH, Hijazi Z, Thomas L et al (2012) Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 33(22): 2821-2830.
33. Harenberg J, Marx S, Erdle S et al (2012) Determination of the anticoagulant effect of new oral anticoagulants: an unmet need. Expert Rev Hematol 5: 107-113.
34. Samama MM, Conard J, Flaujac C et al (2011) Pharmacologic heterogeneity of new anticoagulants. J Mal Vasc 36(suppl 1): 10-15.
35. Institute of Safe Medication Practice-Safety Alert (2012) Signals for dabigatran and metoclopramide. Quarterwatch.
36. European Medicines Agency (2012) European Medicines Agency updates patients and prescriber information for Pradaxa. EMA/337406/2012, Press Office.
37. Eikelboom JW, Quinlan DJ, Connolly SJ et al (2012) Dabigatran efficacy-safety assessment for stroke prevention in patients with atrial fibrillation. J Thromb Haemost 10: 966-968.
38. Levi M, Eerenberg E, Kamphuisen PW (2011) Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. J Thromb Haemost 9: 1705-1712.
39. Paré G, Erikkson N, Lehr T et al (2012) RE-LY-Genetics: genetic determinants of dabigatran plasma levels and their relation to clinical response. European Society of Cardiology 2012 Congress, Munich, Germany.
40. Shah SV, Gage BF (2011) Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 123: 2562-2570.
41. Kamel H, Johnson SC, Easton JD et al (2012) Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke 43: 881-883.